Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alveolus' Aero pulmonary stent:

This article was originally published in Clinica

Executive Summary

Alveolus has received US FDA 510(k) clearance to market its Aero hybrid tracheobronchial stent for treating malignant pulmonary obstructions. Malignant pulmonary obstruction causes difficulty in breathing, a condition that often requires hospitalisation, explained the Charlotte, North Carolina firm. A stent may improve the condition while reducing a patient's hospital stay. In addition to pulmonary stents, Alveolus' current portfolio of FDA-cleared and CE-marked products include oesophageal stents, guidewires and stent sizing devices.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel